Genmab — Februar 2019
-
Helge, udsagnet "Nu er det ikke alle, der er lige så useriøse omkring guidance som Genmab", må man da læse som at ledelsen er useriøs. Hvem ellers... selskabet selv?
Og det synes jeg ikke er i orden at sige. Det er derimod respektløst. Ovenikøbet sagt af en person, som man må antage, IKKE har lige så gode kvalifikationer til at styre et biotekselskab, som dem der sidder i GENs ledelse. -
Du fik det sidste ord kkjoel..Nu koger vi ikke mere suppe på den pind.
-

-
well, jeg har faktisk regnet forkert. Da jeg sagde 4 dage regnede jeg kun us salg. medregnet row var vi kun 2,5 dage over 2b...
-
Det må være umådeligt svært at skulle guide omsætning, Man er sikker på klø bare man rammer lidt ved siden af.. Jeg syntes at de rammer utroligt godt...
-
me too. the discounts screwed it up. i feel you could blame David for not being on top of that; i doubt he will make that mistake again... In addition, as milestone level and size had not been made public until the event, it would have been really difficult/awkward to adjust guidance on that, even if they felt they would fail 2bn.
-
true - but think about what we have learned as investors about the guidance interval and the risks associated with major milestones
-
going forward, how will these things be interpreted by the market
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind